Going in the opposite direction, Positive trails results shouldn’t lead to Helus Pharma stock tumbling 21%
Landon Capital News
Helus Pharma Inc. (NASDAQ: HELP) shares fell 21% on Monday despite the company announcing positive topline results from its Phase 3 APPROACH study of HLP003 as an adjunctive treatment for major depressive disorder.
HLP003 met the study’s primary endpoint, delivering a 7.6-point placebo-adjusted improvement from baseline at Week 6 on the Montgomery-Asberg Depression Rating Scale (MADRS) (p<0.0001). The treatment showed a rapid onset of action, with a statistically significant 5.0-point placebo-adjusted reduction as early as Day 2 (p=0.0013).
The study enrolled 222 participants with moderate to severe major depressive disorder, all of whom continued on a stable dose of antidepressant medication throughout the trial. Baseline MADRS total scores were 32.7 in the HLP003 group and 33.8 in the placebo group.
The effect was durable through Week 12, a key secondary endpoint, with a 7.0-point placebo-adjusted improvement from baseline (p<0.0001). Response rates with HLP003 were 50.0% at Day 2, 56.3% at Week 6 and 45.5% at Week 12, compared with 23.6%, 28.2% and 19.1%, respectively, for placebo.
Remission rates were 39.3% at Day 2, 50.9% at Week 6 and 40.2% at Week 12 for HLP003, versus 15.5%, 18.2% and 15.5% for placebo.
About Landon Capital News
Landon Capital News is a media company that is wholly owned by Landon Capital Management LLC. Landon Capital News distributes economic, and political news in over 176 countries. Landon Capital News provides an in depth and simplistic look at financial, economic, and political news, as it is happening. We also provide our viewers with in-depth analysis on various companies and political news that directly correlate to economics. We bridge the gap of information between the investor and the markets, sectors and industries that they invest. For more information, please contact us at info@landoncapital.net or 404-995-6671 or visit https://landoncapital.net.
Safe Harbor Statement
This release does not constitute an offer to sell or a solicitation of any kind. This press release is the news that we have researched to be true and accurate to our best ability. Landon Capital does not share the sentiment of the news that is released, we are just reporting a news event. Landon Capital received no direct compensation related to this release. This release may contain certain forward-looking statements based on current expectations, forecasts and assumptions that involve risks and uncertainties. Forward-looking statements in this release are based on information available to us as of the date hereof through already public resources. Actual results may differ materially from those stated or implied in.